Home/Filings/4/0001093557-23-000197
4//SEC Filing

Dolan Matthew Vincent 4

Accession 0001093557-23-000197

CIK 0001093557other

Filed

Aug 31, 8:00 PM ET

Accepted

Sep 1, 6:40 PM ET

Size

5.1 KB

Accession

0001093557-23-000197

Insider Transaction Report

Form 4
Period: 2023-09-01
Dolan Matthew Vincent
EVP, Strategy & Corporate Dev
Transactions
  • Sale

    Common Stock

    2023-09-01$102.32/sh56$5,73033,569 total
Footnotes (2)
  • [F1]On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan which was amended on December 6, 2022. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. he shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
  • [F2]Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

Issuer

DEXCOM INC

CIK 0001093557

Entity typeother

Related Parties

1
  • filerCIK 0001914994

Filing Metadata

Form type
4
Filed
Aug 31, 8:00 PM ET
Accepted
Sep 1, 6:40 PM ET
Size
5.1 KB